AKST4290

DRUG4 trials

Sponsors

Alkahest, Inc.

Conditions

Diabetic RetinopathyNeovascular Age-related Macular DegenerationParkinson DiseasePemphigoid, Bullous

Phase 2

A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

CompletedNCT04331730

Alkahest, Inc.Neovascular Age-related Macular Degeneration

Start: 2020-01-28End: 2021-09-16Updated: 2022-10-26

Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment

CompletedNCT04369430

Alkahest, Inc.Parkinson Disease

Start: 2020-01-16End: 2021-03-10Updated: 2022-10-10

A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid

TerminatedNCT04499235

Alkahest, Inc.Pemphigoid, Bullous

Start: 2020-01-30End: 2021-04-14Updated: 2023-09-14

A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

TerminatedNCT05038020

Alkahest, Inc.Diabetic Retinopathy

Start: 2021-08-17End: 2022-04-19Updated: 2023-11-01